The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

Are you on a weight loss journey but struggling to shed those extra kilos? You're not alone. Many people often feel lost about what to eat and do to reach their fitness goals, sometimes blindly ...

To the editor: All Republicans on the Senate Committee on Health, Education, Labor and Pensions — including members who are physicians — voted to confirm Robert F. Kennedy Jr. to regulate ...

The rapper was slated to perform in two shows at the Tokyo Dome in May. But, after his shocking Grammy stunt, he might lose a whooping 20 million dollar international concert deal as the ...